How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Noorossadat Seyyedi et al., adding:
”The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Von Willebrand factor is normally made only by endothelial cells and megakaryocytes, yet some cancers switch it on.
Across 100 VWF-positive cancer lines, this study tied that aberrant expression to the mutant p53R175H, which engages the repressor NF-IB and activator GATA6 to drive VWF from the promoter.
The resulting VWF fueled cancer cell to platelet aggregates, and plakoglobin reversed the effect.”
Title: The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Authors: Noorossadat Seyyedi, Chu Shiun Lo, Parnian Alavi, Manijeh Pasdar, Nadia Jahroudi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge